Colon Targeting Drug Delivery Market Report 2026

Colon Targeting Drug Delivery Market Overview

• Colon Targeting Drug Delivery market size has reached to $1.5 billion in 2025 • Expected to grow to $2.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rising Gastrointestinal Disease Prevalence Fueling Market Growth Due To Increasing Demand For Targeted Treatment • Market Trend: Innovative Drug Delivery Solutions Driving Market Growth Due To Enhancing Targeting And Therapeutic Efficacy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Colon Targeting Drug Delivery Market?

Colon targeting drug delivery refers to a specialized drug delivery system designed to release therapeutic agents specifically in the colon, enhancing treatment efficacy for local diseases such as inflammatory bowel disease and colorectal cancer, while minimizing systemic side effects and improving patient compliance. The main dosage forms of colon targeted drug delivery are tablets, capsules, microspheres, nanoparticles, and others. Tablets are solid, compressed forms of medication designed for oral intake. In colon targeted drug delivery, tablets are often coated with special materials that prevent the drug from dissolving in the stomach or small intestine. Instead, they dissolve in the colon, ensuring the medication is released precisely where it's needed. It utilizes different technologies such as pH-sensitive systems, time-dependent systems, microbially triggered systems, pressure-controlled systems, and others, which are applied in the treatment of conditions such as inflammatory bowel disease, colorectal cancer, infectious diseases, and others, and are primarily used by end users including hospitals, clinics, research institutes, and others.

What Is The Colon Targeting Drug Delivery Market Growth Forecast?

The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to $2.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, expansion of colorectal cancer therapies, innovation in microbially triggered systems, increasing pharmaceutical R&D investments, demand for patient-centric drug delivery solutions. Major trends in the forecast period include increasing focus on targeted drug delivery systems, growing use of pH-sensitive and time-dependent technologies, rising adoption for inflammatory bowel disease treatment, expansion of colon-specific cancer therapies, development of advanced oral dosage forms.

What Is The Driver Of The Colon Targeting Drug Delivery Market?

The rising prevalence of gastrointestinal diseases is expected to propel the growth of the colon targeting drug delivery market going forward. Gastrointestinal diseases refer to disorders affecting the digestive tract, including the stomach, intestines, and associated organs. The prevalence of gastrointestinal diseases is growing due to unhealthy dietary habits, which include excessive consumption of processed foods and low fiber intake that disrupt gut health and digestion. Colon targeting drug delivery is used in gastrointestinal diseases to ensure precise drug release at the site of inflammation or infection, enhancing therapeutic effectiveness and reducing systemic side effects. For instance, in June 2023, according to Crohn's and Colitis Canada, a nonprofit organization, the number of individuals affected by inflammatory bowel disease is projected to increase from 322,600 in 2023 (representing 0.8% of the population) to 470,000 by 2035 (1.1% of the population). Therefore, the rising prevalence of gastrointestinal diseases is driving the growth of the colon targeting drug delivery industry.

Key Players In The Global Colon Targeting Drug Delivery Market

Major companies operating in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., Tharimmune Inc.

Global Colon Targeting Drug Delivery Market Trends and Insights

Major companies operating in the colon targeting drug delivery market are focusing on developing innovative drug delivery solutions, such as functional oral dosage forms, to improve targeted drug release, enhance therapeutic efficacy, and minimize side effects. Functional oral dosage forms are used in colon targeting drug delivery to protect active pharmaceutical ingredients from degradation in the upper gastrointestinal tract and ensure their controlled release specifically in the colon. For instance, in September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology for the targeted delivery of oral drugs to the colon. This advanced solution enables precise release by using pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring the API reaches the colon intact. By enabling oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional supports the development of patient-friendly therapies and expands the possibilities for treating chronic gastrointestinal disorders with greater accuracy and reduced systemic exposure.

What Are Latest Mergers And Acquisitions In The Colon Targeting Drug Delivery Market?

In October 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Telavant Holding Inc. for $7.1 billion. This acquisition enhances Roche’s colon-targeting drug delivery portfolio by incorporating RVT-3101, further advancing its efforts in treating inflammatory bowel diseases. Telavant Holding Inc. is a US-based biopharmaceutical company that specializes in developing therapies for gastrointestinal diseases.

What Defines the Colon Targeting Drug Delivery Market?

The colon targeting drug delivery market includes revenues earned by entities by providing services such as formulation development, preformulation studies, drug delivery technology licensing, coating and encapsulation services, and in-vitro release testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Colon Targeting Drug Delivery Market Report 2026?

The colon targeting drug delivery market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the colon targeting drug delivery industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.